MX375073B - Cristal de acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico. - Google Patents

Cristal de acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico.

Info

Publication number
MX375073B
MX375073B MX2017006000A MX2017006000A MX375073B MX 375073 B MX375073 B MX 375073B MX 2017006000 A MX2017006000 A MX 2017006000A MX 2017006000 A MX2017006000 A MX 2017006000A MX 375073 B MX375073 B MX 375073B
Authority
MX
Mexico
Prior art keywords
fluoropyrrolidine
cyclopropylamino
dihydroquinoline
fluoroethyl
oxo
Prior art date
Application number
MX2017006000A
Other languages
English (en)
Spanish (es)
Inventor
Akinori Goto
Ichiro Araya
Keiko Funada
Muneki Nagao
Wataru Minagawa
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX375073(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of MX375073B publication Critical patent/MX375073B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017006000A 2011-11-10 2012-11-09 Cristal de acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico. MX375073B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011246209 2011-11-10
JP2012071739 2012-03-27
PCT/JP2012/007195 WO2013069297A1 (ja) 2011-11-10 2012-11-09 7-{(3s、4s)-3-[(シクロプロピルアミノ)メチル]-4-フルオロピロリジン-1-イル}-6-フルオロ-1-(2-フルオロエチル)-8-メトキシ-4-オキソ-1、4-ジヒドロキノリン-3-カルボン酸の結晶

Publications (1)

Publication Number Publication Date
MX375073B true MX375073B (es) 2025-03-06

Family

ID=48289529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006000A MX375073B (es) 2011-11-10 2012-11-09 Cristal de acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico.

Country Status (17)

Country Link
US (3) US9090587B2 (enExample)
EP (2) EP2778159B1 (enExample)
JP (4) JP5871948B2 (enExample)
KR (2) KR102162208B1 (enExample)
CN (2) CN103930414B (enExample)
AU (1) AU2016273899B2 (enExample)
BR (1) BR112014010765B1 (enExample)
CA (1) CA2855022C (enExample)
ES (2) ES2747303T3 (enExample)
IN (1) IN2014DN03277A (enExample)
MX (1) MX375073B (enExample)
NZ (1) NZ623808A (enExample)
RU (2) RU2615509C2 (enExample)
SA (1) SA112330992B1 (enExample)
SG (2) SG11201401817TA (enExample)
TW (1) TWI547492B (enExample)
WO (1) WO2013069297A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
JP5651812B1 (ja) * 2013-04-25 2015-01-14 杏林製薬株式会社 固形医薬組成物
JP5700740B1 (ja) * 2013-04-25 2015-04-15 杏林製薬株式会社 固形医薬組成物
JP6349306B2 (ja) * 2013-04-25 2018-06-27 杏林製薬株式会社 錠剤
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US20170246160A1 (en) * 2014-10-23 2017-08-31 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
JP6018334B2 (ja) * 2014-10-23 2016-11-02 杏林製薬株式会社 固形医薬組成物
JP6077725B1 (ja) * 2015-03-13 2017-02-08 杏林製薬株式会社 呼吸器感染症治療剤
CA2988092A1 (en) 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
CA2987879A1 (en) 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
US10206917B2 (en) * 2015-06-02 2019-02-19 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
MX2019014931A (es) 2017-06-16 2020-02-13 Kyorin Seiyaku Kk Agente terapeutico para neumonia por aspiracion, supuracion pulmonar, o absceso pulmonar.
CN116549446A (zh) * 2017-06-16 2023-08-08 杏林制药株式会社 吸入性肺炎、肺化脓或肺脓肿的治疗剂
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA944369B (en) * 1993-08-27 1995-02-13 Hokuriku Seuyaku Co Ltd 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
CN1158846A (zh) * 1995-05-09 1997-09-10 昆山市康壮达兽药厂 盐酸氟哌酸的合成工艺
US20030124028A1 (en) * 2001-08-10 2003-07-03 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
JPWO2003076428A1 (ja) * 2002-03-08 2005-07-07 第一製薬株式会社 キノロンカルボン酸誘導体
DK1666477T3 (da) 2003-09-10 2013-07-29 Kyorin Seiyaku Kk 7-(4-trisubstitueret 3-cyclopropylaminomethyl-1- pyrrolidinyl)-quinoloncarboxylsyre-derivat
CN101003540A (zh) * 2006-01-18 2007-07-25 广州白云山制药股份有限公司广州白云山制药总厂 一种抗感染化合物和用途
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي

Also Published As

Publication number Publication date
CA2855022C (en) 2019-05-07
NZ623808A (en) 2015-07-31
RU2615509C2 (ru) 2017-04-05
JP2018158949A (ja) 2018-10-11
CA2855022A1 (en) 2013-05-16
JP5871948B2 (ja) 2016-03-01
AU2016273899B2 (en) 2017-07-27
ES2747303T3 (es) 2020-03-10
US9328089B2 (en) 2016-05-03
JP6349435B2 (ja) 2018-06-27
AU2012337206A8 (en) 2016-09-22
AU2016273899A1 (en) 2017-01-12
RU2017109814A (ru) 2019-01-23
KR20190065456A (ko) 2019-06-11
RU2014123567A (ru) 2015-12-20
BR112014010765B1 (pt) 2020-07-14
TWI547492B (zh) 2016-09-01
EP3112359B1 (en) 2019-08-21
EP2778159B1 (en) 2017-03-01
US20150284361A1 (en) 2015-10-08
ES2621664T3 (es) 2017-07-04
USRE47785E1 (en) 2019-12-31
CN103930414B (zh) 2016-01-20
AU2012337206A1 (en) 2014-05-22
CN104945375B (zh) 2017-07-04
CN103930414A (zh) 2014-07-16
EP2778159A1 (en) 2014-09-17
AU2012337206B2 (en) 2016-09-15
TW201332991A (zh) 2013-08-16
US9090587B2 (en) 2015-07-28
EP3112359A1 (en) 2017-01-04
BR112014010765A2 (pt) 2017-06-13
JP6514069B2 (ja) 2019-05-15
CN104945375A (zh) 2015-09-30
JP2017160243A (ja) 2017-09-14
WO2013069297A1 (ja) 2013-05-16
SG10201608167UA (en) 2016-11-29
EP2778159A4 (en) 2015-06-03
SG11201401817TA (en) 2014-08-28
SA112330992B1 (ar) 2015-09-13
KR102162208B1 (ko) 2020-10-06
KR20140098074A (ko) 2014-08-07
JP6818719B2 (ja) 2021-01-20
JPWO2013069297A1 (ja) 2015-04-02
IN2014DN03277A (enExample) 2015-05-22
US20140288310A1 (en) 2014-09-25
JP2016027045A (ja) 2016-02-18
RU2017109814A3 (enExample) 2020-04-08

Similar Documents

Publication Publication Date Title
MX375073B (es) Cristal de acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico.
NZ734896A (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
IN2014MN02106A (enExample)
BR112013002182A2 (pt) derivados de quinolina e inibidores de melk contendo os mesmos
PH12016500169A1 (en) Polymorph of syk inhibitors
EA033513B1 (ru) Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
MX2015005286A (es) Procedimiento para la preparación de derivados del ácido biliar.
PT2411395E (pt) Derivados de furopirimidinadiona como moduladores de trpa1
SA515361086B1 (ar) Fasn مركبات وتركيبات جديدة لتثبيط
WO2014128545A3 (en) An improved process for the preparation of dolutegravir
WO2012131710A3 (en) Novel process for the synthesis of indoline derivatives
WO2013098836A8 (en) A bis-quinophthalone pigment and a process for preparing the same
CY1118079T1 (el) Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης
MX2011009898A (es) Proceso para la obtencion de derivados de acido propionico.
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.
IN2015DN02424A (enExample)
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
UA117849C2 (uk) Спосіб одержання 3-заміщених складних ефірів (індол-1-іл)-оцтової кислоти
MX347693B (es) Cristal del acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluorop irrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidr oquinolin-3-carboxilico.
MX2015017864A (es) Metodo de preparacion de derivados de acido pirrolidina-2-carboxil ico.
EA201790522A1 (ru) Соль производного цефалоспорина, ее кристаллическое твердое вещество и способ ее получения
PH12012502478A1 (en) Isoquinoline derivative
MY168434A (en) Novel acetic acid ester compound or salt thereof
EA201400269A1 (ru) Способ синтеза соединений 7,8-диметокси -1,3-дигидро-2h-3-бензазепин-2-она и применение в синтезе ивабрадина
GEP20156369B (en) New process for synthesis of ivabradine and addition salts therewith pharmaceutically acceptable acid